论文部分内容阅读
最初缺血修饰血清蛋白(ischemiac modified albumin,IMA)是作为一种检测心肌急性缺血的新型生化指标而被发现的,尽管我们对于它的结构尚无清晰的认识,但研究者通过白蛋白钴结合法(albumin cobalt binding assay,ACB)检测白蛋白对于钴离子的结合力,可间接检测IMA。目前,IMA除应用于急性冠脉综合征的诊断和预后评估的研究之外,还发现其在一些非心源性缺血疾病(如脑卒中、肺栓塞等)的研究中也具有价值。本综述旨在总结近年来IMA在这些缺血性疾病诊断中应用的研究进展。
The initial ischemicacial albumin (IMA) was detected as a new biochemical marker of acute myocardial ischemia. Although we did not know its structure clearly, (Albumin cobalt binding assay, ACB) detection of albumin binding to cobalt ions, indirect detection of IMA. At present, IMA is also used in the diagnosis and prognosis evaluation of acute coronary syndrome, and also finds value in the study of some non-cardiac ischemic diseases such as stroke and pulmonary embolism. This review aims to summarize the recent advances in the application of IMA in the diagnosis of these ischemic diseases.